Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.

Show other versions (1)

OBJECTIVE: To determine the persistence of bactericidal antibody titres following immunisation with serogroup C meningococcal glycoconjugate vaccine at age 6-15 years in order to examine changes in persistence of antibodies with age. DESIGN: Observational study. SETTING: Secondary and tertiary educ...

Full description

Bibliographic Details
Main Authors:	Snape, MD, Kelly, D, Lewis, S, Banner, C, Kibwana, L, Moore, C, Diggle, L, John, T, Yu, L, Borrow, R, Borkowski, A, Nau, C, Pollard, A
Format:	Journal article
Language:	English
Published:	2008

Similar Items

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study
by: Snape, M, et al.
Published: (2008)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
by: De Whalley, P, et al.
Published: (2013)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
by: de Whalley, P, et al.
Published: (2013)

Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
by: Snape, MD, et al.
Published: (2006)

Serogroup c meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
by: Snape, M, et al.
Published: (2006)

Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
by: Perrett, K, et al.
Published: (2010)

Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial
by: Perrett, K, et al.
Published: (2010)

CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.
by: Kelly, D, et al.
Published: (2006)

Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
by: Pollard, A, et al.
Published: (2013)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine
by: De Whalley, P, et al.
Published: (2011)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
by: de Whalley, P, et al.
Published: (2011)

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
by: Dold, C, et al.
Published: (2023)

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
by: Snape, MD, et al.
Published: (2009)

Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.
by: Snape, MD, et al.
Published: (2005)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine
by: O'Connor, D, et al.
Published: (2014)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine.
by: O'Connor, D, et al.
Published: (2014)

Will booster doses be required for serogroup B meningococcal vaccine?
by: McQuaid, F, et al.
Published: (2014)

Serogroup B meningococcal vaccines-an unfinished story.
by: Sadarangani, M, et al.
Published: (2010)

Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy.
by: Jeppesen, C, et al.
Published: (2015)

Challenges and progress in the development of a serogroup B meningococcal vaccine.
by: Lewis, S, et al.
Published: (2009)

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
by: Snape, MD, et al.
Published: (2006)

Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
by: Snape, MD, et al.
Published: (2010)

B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.
by: Perrett, K, et al.
Published: (2012)

Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.
by: Kelly, D, et al.
Published: (2009)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine
by: Blanchard-Rohner, G, et al.
Published: (2012)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
by: Blanchard-Rohner, G, et al.
Published: (2012)

Meningococcal disease serogroup C
by: Cuevas IE, et al.
Published: (2012-03-01)

Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.
by: Khatami, A, et al.
Published: (2011)

Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
by: Xie, O, et al.
Published: (2013)

Plasma and memory B-cell kinetics in infants following a primary schedule of CRM197-conjugated serogroup C meningococcal polysaccharide vaccine (vol 127, pg 134, 2009)
by: Kelly, D, et al.
Published: (2011)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
by: Snape, MD, et al.
Published: (2013)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
by: Snape, M, et al.
Published: (2013)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
by: Read, R, et al.
Published: (2014)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial
by: Read, R, et al.
Published: (2014)

The beginning of the end for serogroup B meningococcus?
by: Snape, MD, et al.
Published: (2013)

The beginning of the end for serogroup B meningococcus?
by: Snape, MD, et al.
Published: (2013)

Protecting UK adolescents and adults against meningococcal serogroup B disease
by: Andrew Vyse, et al.
Published: (2018-03-01)

A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
by: Su, E, et al.
Published: (2011)

Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
by: Mariëtte B van Ravenhorst, et al.
Published: (2018-01-01)

Meningococcal serogroup B vaccines: Estimating breadth of coverage
by: Robert G. K. Donald, et al.
Published: (2017-02-01)